"Lenacapavir, the first twice-yearly HIV prophylactic in the world, is set to be rolled out in Zimbabwe, one of ten countries selected for the initial rollout of the injectable drug. "We are excited to announce that Zimbabwe was selected as one of the ten countries globally to roll out lenacapavir, a breakthrough development in the fight against HIV," the US Embassy in Harare said in a post on X."
"Zimbabwe has one of the highest HIV prevalence rates in the world, with 1.3 million people living with the condition, according to figures from UNAIDS, the United Nations program on HIV/AIDS. The southern African nation recently met the UNAIDS 9595-95 fast-track targets, meaning that 95% of those living with HIV know their status; 95% of those who know they have HIV are on life-saving anti-retroviral treatment; and 95% of people on treatment achieve viral suppression."
"Dr. Ponesai Nyika, a public health expert with extensive experience in HIV/AIDS research and program implementation, told DW that Zimbabwe has a "very solid HIV response infrastructure." The introduction of lenacapavir is expected to greatly boost Zimbabwe's efforts to eradicate infections. "Supported by strong partnerships like PEPFAR [the US President's Emergency Plan for AIDS Relief] and other local institutions. "So, this creates a solid foundation for the introduction of lenacapavir."
Lenacapavir, the first twice-yearly injectable HIV prophylactic, will be deployed in Zimbabwe as one of ten initial rollout countries. Zimbabwe has about 1.3 million people living with HIV and ranks among countries with the highest prevalence. The country recently achieved UNAIDS 95-95-95 targets, reflecting strong testing, treatment uptake, and viral suppression. Public health experts highlight a very solid HIV response infrastructure supported by partnerships such as PEPFAR and local institutions, creating a foundation for lenacapavir introduction. The rollout will prioritize people susceptible to HIV, including adolescent girls and those who are pregnant or breastfeeding. WHO hails lenacapavir as "the next best thing."
Read at www.dw.com
Unable to calculate read time
Collection
[
|
...
]